“The acquisition of Silken Berlaymont is industrially sound and is made at an attractive valuation. The hotel is positioned in a market segment with good average prices and a stable base occupancy level. The hotel product is underperforming and offers good improvement potential supported by inter alia its strong location adjacent to the EU Commission with efficient communications to both the city centre and the airport. The hotel property adds further value to Pandox’s already strong hotel portfolio in Brussels”, says Anders Nissen, CEO of Pandox.
The transaction is in form of an acquisition of a selection of assets and liabilities, including the building and the hotel business. The purchase price amounts to MEUR 30, plus transfer tax of maximum MEUR 2.7. In addition, MEUR 3.5 will be invested in upgrading of rooms, corridors, public areas and meeting areas. The total investment corresponds to a yield in excess of 7 percent. The seller is Hotel Berlaymont SA/Urvasco Hotel SA via trustee where Pandox has received the necessary court approval to enter into an agreement to acquire the hotel. The hotel will initially be operated under an independent brand.
FOR MORE INFORMATION, PLEASE CONTACT:
Anders Nissen, CEO, +46 (0) 708 46 02 02
Liia Nõu, CFO, +46 (0) 702 37 44 04
Anders Berg, Head of Communications and IR, +46 (0) 760 95 19 40
The information was submitted for publication, through the agency of the contact persons set out above, 7 April 2017, 08:00 CEST.
Pandox is a leading owner of hotel properties in Northern Europe with a focus on sizeable hotels in key leisure and corporate destinations. Pandox’s hotel property portfolio comprises 120 hotels with more than 26,000 hotel rooms in ten countries. Pandox’s business is organised into Property Management, which comprises hotel properties leased on a long-term basis to market leading regional hotel operators and leading international hotel operators, and Operator Activities, which comprises hotel operations executed by Pandox in its owner-occupied hotel properties. Pandox was founded in 1995 and the company’s B shares are, as of 18 June 2015, listed on Nasdaq Stockholm. www.pandox.se